PLA2G12B

Across TCGA pan-cancer cohorts, PLA2G12B mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of PLA2G12B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PLA2G12B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PLA2G12B is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC and LSCC are the cancer types where PLA2G12B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLA2G12B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−1.383	<.001	11	view →
LSCC	Male	II,III,IV	−1.390	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

PLA2G12B–CCRCC

Open the CCRCC breakdown →